Aquestive Therapeutics (AQST) announced the United States Patent and Trademark Office, USPTO, has issued two additional U.S. patents related to Anaphylm, the Company’s novel epinephrine prodrug sublingual film. “We are pleased with the issuance of these additional patents for Anaphylm, extending protection for the product through at least 2037,” said Dan Barber, President and CEO of Aquestive. “These claims cover the proprietary composition for Anaphylm, which enables the oral sublingual film delivery of an epinephrine prodrug. By leveraging our proprietary technology platforms, PharmFilm(R) and Adrenaverse(TM), in this inventive way, we are addressing significant unmet needs in severe allergic reactions, while reinforcing patent protection for Anaphylm. These patents are the result of a broad intellectual property strategy that includes many other multi-continent patent applications pending and planned.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Advances Anaphylm Clinical Development
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Aquestive Therapeutics Highlights at Global Investor Conference
- Aquestive Therapeutics price target raised to $8 from $7 at Oppenheimer
- Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy Market